Publikace
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Farmaceutická fakulta v Hradci Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Farmaceutická fakulta v Hradci Králové
- Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Farmaceutická fakulta v Hradci Králové
- Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment2018 | Farmaceutická fakulta v Hradci Králové
- Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment2015 | Farmaceutická fakulta v Hradci Králové
- Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors2014 | Farmaceutická fakulta v Hradci Králové
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
Loading network view...